AOAndrew OwenBSS, MSC, PhD, FSBVideoHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #35 Can Low-Cost Oral Alternatives Be Used in Place of Oral Lenacapavir When Initiating Long-Acting Lenacapavir PrEP in Low- and Middle-Income Countries? - Andrew OwenView Video
VideoHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #16 Inter- and Intraindividual Variability of Long-Acting Cabotegravir/Rilpivirine Pharmacokinetics after 1 Year of Continuous Use - Shawnalyn SunagawaView Video
VideoHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #15 Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Virologically Suppressed Adolescents Living with HIV-1 in Sub-Saharan Africa: Data from the LATA Trial - Lisanne BeversView Video
VideoHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #14 Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Seminal Plasma throughout the Dosing Interval - Noah NeveretteView Video
VideoHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #13 Intracellular Carbovir- and Lamivudine-Triphosphate Concentrations in PBMC and DBS among Children with HIV-1 Receiving ABC/DTG/3TC: Results from IMPAACT 2019 - Stefanie SchwabView Video
VideoHIVTuberculosis26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #12 Pharmacokinetics of Abacavir and Lamivudine in Infants with and without Rifampicin Co-Treatment - Laize BecaView Video
VideoHIVTuberculosis26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #11 A Preliminary Analysis of the Impact of Pharmacogenetic Variation on Bictegravir and Dolutegravir Concentrations in Individuals with HIV and Tuberculosis - Anushka NaidooView Video
VideoHIVTuberculosis26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #10 Drug Interactions Between Probe Drugs Dolutegravir (DTG), Midazolam (MDZ) and Digoxin (DIG) with Escalating Doses of Rifampicin (RIF): DORIS Study - Laura DickinsonView Video
VideoTuberculosis26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #9 Physiologically Based Pharmacokinetic Modeling to Inform Lenacapavir Dose Regimen When Co-Administered with Rifamycins in Participants with Tuberculosis - Sara SalernoView Video
JCJessica CusatoBSc, MSc, PhDVideoViral Hepatitis and Liver Disease26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #8 Pharmacogenetic and Pharmacokinetic Profiling of Bulevirtide in Patients with Chronic Hepatitis D: A Preliminary Study - Jessica CusatoView Video
JCJessica CusatoBSc, MSc, PhDVideoViral Hepatitis and Liver Disease26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Pharmacology of HDV - Jessica CusatoView Video
KWCKeith W. CrawfordRPh, PhDVideo26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025NIH Initiatives and Research Promoting Antiviral Pharmacology - Keith W. CrawfordView Video
